Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors | Oncology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

In a previous cohort study, administration of the BNT162b2 vaccine in patients with solid tumors demonstrated a favorable safety and efficacy profile following the second vaccination, although gradual immunogenicity was observed compared with the general population.1 We had previously demonstrated at 6 months postvaccination a steady decline in antibody titers and seropositivity rates among patients with solid tumors treated at a center in Haifa, Israel, that were comparable with the general population.2 Because of declined immunity, a booster dose had been recommended by medical authorities.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: March 30, 2022.

Published Online: April 22, 2022. doi:10.1001/jamaoncol.2022.1467

Corresponding Author: Irit Ben-Aharon, MD, PhD, Division of Oncology, Rambam Health Care Campus, HaAliya HaShniya 8, Haifa, Israel 31096 (i_benaharon@rambam.health.gov.il).

Author Contributions: Dr Ben-Aharon had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Waldhorn and Holland contributed equally.

Concept and design: Waldhorn, Ben-Aharon, Goshen-Lago, Halberthal.

Acquisition, analysis, or interpretation of data: Waldhorn, Ben-Aharon, Goshen-Lago, Holland, Benguigui, Shaked.

Drafting of the manuscript: Waldhorn, Ben-Aharon, Goshen-Lago, Holland, Shaked.

Critical revision of the manuscript for important intellectual content: Waldhorn, Ben-Aharon, Halberthal, Benguigui.

Statistical analysis: Waldhorn, Ben-Aharon, Holland.

Obtained funding: Ben-Aharon.

Administrative, technical, or material support: Ben-Aharon, Goshen-Lago, Benguigui.

Supervision: Ben-Aharon, Halberthal, Shaked.

Conflict of Interest Disclosures: Dr Goshen-Lago reported grants from the Israel Cancer Research Fund during the conduct of the study. No other disclosures were reported.

Role of the Funder/Sponsor: The funding organization (Israel Cancer Research Fund) had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Goshen-Lago  T , Waldhorn  I , Holland  R ,  et al.  Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer.   JAMA Oncol. 2021;7(10):1507-1513. doi:10.1001/jamaoncol.2021.2675PubMedGoogle ScholarCrossref
2.
Waldhorn  I , Holland  R , Goshen-Lago  T ,  et al.  Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors.   Cancer Discov. 2021;11(10):2430-2435. doi:10.1158/2159-8290.CD-21-1072PubMedGoogle ScholarCrossref
3.
Waidhauser  J , Schuh  A , Trepel  M , Schmälter  AK , Rank  A .  Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer.   Cancer Immunol Immunother. 2020;69(1):147-157. doi:10.1007/s00262-019-02449-yPubMedGoogle ScholarCrossref
4.
Keeton  R , Tincho  MB , Ngomti  A ,  et al.  T cell responses to SARS-CoV-2 spike cross-recognize Omicron.   Nature. 2022;603(7901):488-492. doi:10.1038/s41586-022-04460-3PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close